1

Audrey’s Life Science Meeting Picks for Jan. 3, 2016 – August 2016

Complimentary Service of AudreysNetwork.com Jan. 3, 2016

***************************************************************** QB3, Wednesday, Jan. 6, 2016

Topic: “Assessing The Realistic Breadth Of A Patent: Design-Arounds And Claim Strategy” Speaker: Michael Hostetler, Phd, Partner, Wilson Sonsini Goodrich Rosati Date and Time: Wednesday, Jan. 6, 2016, noon to 1:00 pm

Location: QB3@953, 953 Indiana St., San Francisco; QB3@953 has a small parking lot. Please consider these alternatives:

A carsharing service such as Uber or Lyft The lots at 1098 Minnesota St. and 963 Illinois St.

The UCSF Mission Bay parking garages are a 12-minute walk away The Third St. MUNI streetcar

Fees: General admission - $10. See details about cost and registration at https://www.eventbrite.com/e/qed-michael-j-

hostetler-wilson-sonsini-assessing-the-realistic-breadth-of-a-patent-design-arounds-tickets-20115926277?mc_cid=231a748e53&mc_eid=cb4c38a44a

Office hours to follow, 1-3 pm. Contact Doug Crawford for details.

Topic Description Because a patent claim presents the property rights accorded to an invention, interpreting the realistic breadth of the claim is both challenging and important, be it for determining

your rights (if you own the patent), a competitor’s rights (if you are identifying design-around opportunities or infringement red flags), or a potential partner’s rights. This seminar will help you read patent claims, including cracking the infamous Markush claim code found in many pharmaceutical patents.

Speaker Bio Dr. Mike Hostetler is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology industries. He works with both venture-

backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology products in all stages of development, from proof of concept to

regulatory approval. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees.

***********************************************************************

Triple Ring Technologies, Thursday Evening, Jan. 7, 2016

Topic: “Developing Personalized Cartilage Repair”

2

Speaker: Grace D. O'Connell , PhD, is co-director of the Berkeley Biomechanics Laboratory in the Department of Mechanical Engineering at University of California, Berkeley Date and Time: Thursday, Jan. 7, 2016, 6pm-9pm (talk begins at 6:45 pm) Location: Triple Ring Technologies - 39655 Eureka Dr., Newark, CA

The seminar is free, but registration is required for planning purposes. There may be a small number of walk-in spots available. Register Now! http://goo.gl/gGiB82 Topic Description

The musculoskeletal system is comprised of large load-bearing soft tissues that absorb and distribute the complex loads placed on the joint. Degeneration of these tissues, including articular cartilage and the intervertebral disc of the spine, is the leading cause of disability in Americans, contributing to over $130 billion in medical costs. Current treatment options

include replacing the degenerated tissue with a total joint replacement device comprised of metal and plastic components, which significantly alters the loading environment and have a limited lifespan in the body. Recent advances in biological treatment options use cartilage explants or engineered tissues. My work employs a cell-based approach by encapsulating

cells within a soft biomaterial to develop functional cartilage implants in vitro. However, clinical translation of these techniques are challenging due to limited nutrient diffusion. In this talk, I will focus on challenges and advancements towards developing soft biocompatible materials for repair or replacement of cartilaginous tissues.

Speaker Bio Grace D. O'Connell , PhD, is co-director of the Berkeley Biomechanics Laboratory in the Department of Mechanical Engineering at University of California, Berkeley. Before joining

UC Berkeley, Dr. O'Connell conducted postdoctoral research in cartilage tissue engineering with Dr. Clark Hung at the University of Columbia. Dr. O'Connell received her PhD in Bioengineering at the University of Pennsylvania, where her research focused on intervertebral disc biomechanics with age, degeneration, and injury. Currently, her research interests are focused on the mechanobiology of soft tissues in the musculoskeletal system.

Dr. O'Connell's research group is evaluating the effects of injury and repair on cartilage and intervertebral disc mechanobiology.

**************************************************************************

Health Care Web Summit Webinar, Wednesday Afternoon, Jan. 13, 2015 Webinar: “Commercial Agility to Maximize Your Life Sciences Business”

Speakers: Theresa Greco, Vice President, Life Sciences, LexisNexis Health Care; Darryl Williams, Head of Global MDM and Platform Solutions, LexisNexis Health Care Date and Time: Wednesday, Jan. 13, 2015, 11:00 am PT Complimentary

Registration:

Registration is Complimentary for qualified applicants. Applications will be accepted by the Summit co-sponsor according to their criteria. Applicants approved for registration will be notified by Summit within approximately seven business days of application or sooner.

Register at http://register.healthwebsummit.com/lexis011316 to register (All registrations must be received before 12:00 PM Eastern on Tuesday, January 12th.) We look forward to your participation in this event!

Event Description

3

Making smart, profitable decisions in today’s complex and dynamic health care landscape is becoming increasingly more difficult for life sciences organizations. Commercial agility requires a clear view and thorough understanding of the inner workings of its individual operational areas, and the system as a whole. Today, technology enables an unprecedented

level of clarity and understanding made possible by: Collecting massive quantities of data from various systems of care in real time Standardizing, organizing and managing that data in efficient and effective ways

across the enterprise Analyzing, mapping and visualizing various combinations of the data to reveal

meaningful insights and actionable intelligence Every moment, incredible amounts of data about people, providers, payers, networks, claims and more are being gathered. Hidden within that data is valuable information that can be used by life sciences organizations to optimize networks, decrease costs, satisfy

compliance regulations and increase productivity, efficiency and profitability. Join us and discover how a new frontier of data-powered technology is transforming and evolving the way life sciences organizations do business.

Please join LexisNexis Health Care's Theresa Greco and Darryl Williams, on Wednesday, January 13, 2016 at 2PM Eastern for this complimentary, insightful webinar on: Join us for a complimentary webinar and discover:

How you can leverage quality data assets and industry-leading technology to answer

critical life sciences business questions, reduce costs and improve efficiency and compliance

How holistic, cloud-based, real-time data management allows you to interactively engage your data through unique analytic and visualization capabilities

Interested attendees would include:

C-level Executives Analytics Directors and Staff Business Intelligence Directors and Staff

Informatics Directors and Staff Medical Directors Technology Executives Compliance Officers

Operations Executives Innovation and Transformation Executives Other Interested Parties

Attendees would represent organizations including:

Pharmaceutical Organizations PBMs Pharmacies Biotechnology Organizations

Biomedical Device Companies Other Pharmaceutical Stakeholders Speaker Bios

Theresa Greco, Vice President, Life Sciences, LexisNexis Health Care is responsible for LexisNexis sales efforts across the life sciences industry. Prior to her current role, she was head of solution development and commercialization responsible for the extension and expansion of LexisNexis’ solution portfolio across business verticals from R&D on through strategic channel partners.

Theresa has been responsible for the delivery of products and solutions from pre-sales support through discovery, definition, functional design, deployment and post-

4

implementation support. Theresa also leads the expansion of market offerings to meet client needs, including market offerings in Compliance and Master Data Management solutions, from a delivery perspective.

Darryl Williams, PMP, CSM is the Head of Global MDM and Platform Solutions at LexisNexis. He has over 20 years of experience architecting, implementing and managing integration, optimization and strategy programs for initiatives in the life sciences and health care industries focused on the following solution domains: • Master Data Management (MDM)

• Compliance Data Management • Customer Relationship Management (CRM) • Patient Risk Management • Data Warehousing (DW), Business Intelligence (BI), Analytics and Reporting

Darryl focuses on applying Agile Data Management principles and enterprise information management capabilities to a diverse array of business solutions across health care verticals using rich toolsets available via HPCC, the LexisNexis Big Data platform for information management and solutions enablement.

*************************************************************************

sfAWIS Program Meeting, Wednesday Evening, Jan. 13, 2015 Topic: "Does your thinking limit your success?" Speaker: Cassie Chow

Date and Time: Wednesday, January 13, 2016, 6:30-8:30 pm

Location: Genentech, 1 DNA Way, South San Francisco Cost: Online registration: Free for sfAWIS members/students; $10 for non-members. Register by Monday January 11, 2016.

Onsite registration available: $5 for sfAWIS members/students; $15 for non-members. Register at https://www.eventbrite.com/e/does-your-thinking-limit-your-success-tickets-20073824349?ref=ebtnebregn

Topic Description Discover the direction correlation between your “thoughts” and the “results” you see in your life! You’ll take away:

How your assumptions impact the quantity and the quality of your life, money and

success A better understanding of how the mind works and ways to use it to your advantage Tools you can use to break out of your current limitations

And so much more!

Speaker Bio Cassie Crow is a presenter with Productive Learning, a unique personal growth company that has been helping clients develop the innate ability to create and live the life they really want for the past five years. With the world in front of her, and numerous opportunities

after completing graduate school, Cassie discovered that all paths lead to nowhere without the right mindset. She had her first experience of personal growth in 2008 and the

5

experience so moved her that she has made it her life’s work to share the experience with as many people as possible. Cassie believes there is no good reason to live without the experiences that made us feel fully alive. We all deserve to experience the highest version of ourselves.

This event is open to all scientists and non-scientists. You do not need to be an AWIS member to attend. Light dinner provided.

For additional information, check http://www.sfawis.com/ *********************************************************************

Seminar At Stanford, Mid Day, Thursday, Jan. 14, 2016 Topic: “Cell Survival Under Starvation”

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360 Small Lunch Served At 12:00 pm; Lectures Begin At 12:15 pm Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360 Pre-Seminar Speaker: Kang Shen, Departments Of Biology And Pathology

Seminar Speaker: Jennifer Lippincott-Schwartz, NIH Date And Time: January 14, 2016, 12 Noon

***************************************************************** JLABS, Thursday Morning, Jan. 14, 2015 Event: “X Marks the spot:The treasure map to value creation in medical devices.” Speaker: Sarah F. Fisher | Director, Global Market External Innovation, Johnson & Johnson

Medical Devices Date and Time: Thursday, Jan. 14, 2015, 10:30 am Agenda 10:30 AM | Registration Opens

11:00 AM | Presentation and Q&A 12:00 PM | Networking Lunch 1:00 PM | One-on-one Meetings* 5:00 PM | Close

Location: JLABS, 329 Oyster Point Blvd, 3rd Floor,South San Francisco, California Fees: General Public - $35; Student/Academic - $20 Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain

open until noon on January 13th, 2016 (or sold out). One-on-One Meeting

FREE | Application FREE | Accepted Companies *Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on December 31st, 2015. Your application will be reviewed and you

will be notified of acceptance on January 5th, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

6

Details and registration at http://www.eventbrite.com/e/x-marks-the-spot-the-treasure-map-to-value-creation-in-medical-devices-tickets-19740409095?aff=blast Program Overview

Still wondering where your market is? Thinking about the next pivot? Confused as to why your business model canvas has not reaped revenues? Then join us on January 14th to take a deep dive into realizing your projected value and whether you need to change your trajectory. Start maximizing value extraction before others start questioning who stole your returns.

Attendees will have the opportunity to apply ahead of time to meet 1-on-1 with the session presenter, Sarah Fisher, who has 13 years of medical device/pharmaceutical experience in global corporate entrepreneurial ventures.

Sarah has led 4 new business launches in multiple product categories, across international markets and collaborated on several cross-functional projects including operations, regulatory, quality, clinical, R&D, and finance.

The private meetings will touch upon the following: • Who's plan is it anyway? Provide insights on your current business plan, business model canvas, and milestone targets/performance • Who matters most? Stakeholder impact reviews and risk assessments/mitigation

plans • Execution excellence: Focused review on your plans for market validation, concept to commercial, and how to validate your value proposition effectively

Speaker Bio Sarah F. Fisher,Director, Global Market External Innovation, Johnson & Johnson Medical Devices specializes in global go-to-market and commercialization strategies for novel technology introductions with a focus on business models, strategic partnerships, and

integration and execution excellence, primarily within new business units. She started her career with J&J in New York City, and has a combined 13 years of cross-functional innovation experience across medical device and pharmaceutical new business

units within the J&J portfolio of companies. Sarah's passion for entrepreneurial ventures has led her to drive 5 different intrapreneurial ventures, and one post- acquisition commercial integration effort. She was awarded the first ever Corporate Entrepreneur accolade by Corporate Entrepreneurs, LLC in 2010. Sarah is passionate about demonstrating

connectivity to the entrepreneurial ecosystem by advising select start-ups and various public and private stakeholder groups on novel technology go to market models, commercial strategy and corporate entrepreneurship. She is focused on creating and driving innovation efforts that result in value-based access to novel and effective medical solutions across

global markets. ************************************************************************* QB3 Workshop, Jan. 18- March 21, 2016

Event: “GET YOUR STARTUP FUNDED. TAKE THE QB3 SBIR WORKSHOP, OFFERED AT UC BERKELEY AND UCSF” UCSF Nine sessions Dates: Starts Thurs. Jan. 28, ends Thurs. Mar. 31 Location: Byers Hall, UCSF Mission Bay

hare QB3 NIH/NSF SBIR Workshop Spring 2016 at UCSF Event Details

7

Register now for the QB3 NIH/NSF SBIR Workshop UCSF Mission Bay UCSF SBIR course description

Five two-and-a-half hour SBIR classes, with two additional one-hour sessions on Phase 2 submissions and resubmissions, and two additional one-hour sessions on NSF submissions. Starting Thursday, January 28th and concluding Thursday, March 31st. There are a limited number of seats, so please sign up as soon as possible by registering

here on Eventbrite. This five-session workshop will take you through all the steps necessary to successfully file a well-written SBIR/STTR grant application for the April 5 NIH deadline and the June 8 NSF deadline. This course will focus on crafting a well-structured research plan, getting

persuasive letters of support, crafting an efficient budget, and helping you anticipate reviewers’ comments. We will help you speed through the application instructions, saving you hours of time. The course culminates in a submission clinic that will ensure your application is correctly filed.

One or more team members from the company should be prepared to attend every session. Remember to bring your laptop; these will be working sessions. Course includes • Five 2.5-hour working sessions

• One 1-hour resubmission working session • One 1-hour Phase 2 working session • Two 1-hour NSF working sessions • Pre-submission review of specific aims by our course instructors

Topics include • Understanding the requirements of an SBIR • Preparing to apply for an SBIR (company formation, registration at all required websites, identifying the best PI) • Assembling all the necessary parts of the application (letters of support, sub-contract

quotes and letters, facilities to execute the grant, and research plan) • Composing a competitive research plan • Understanding and assembling a budget and justification • Documentation required to use human samples, vertebrate animals, select agents,

resources • Composing competitive innovation and significance sections as well as specific aims • Searching for program announcements and finding opportunities • Assembling and filing (completing the 424 correctly and filing on time)

Schedule Dates Time Location Agenda 1/28 (Thurs) 1:00-3:30 pm BH-212 SBIR session 1

2/11 (Thurs) 1:00-4:30 pm BH-212 SBIR session 2 + NSF session 1 2/25 (Thurs) 1:00-4:30 pm BH-212 SBIR session 3 + NSF session 2 3/17 (Thurs) 1:00-4:30 pm BH-212 SBIR session 4 + Phase 2 session

3/31 (Thurs) 1:00-4:30 pm BH-212 SBIR session 5 + SBIR resubmission session

Standard rate for the entire 14-hour workshop: $750 per company

8

Discounted rate for UC affiliates, QB3 Startup in a Box Members, and QB3 Accelerator Members: $250 for entire course per company Startup in a box membership fee for new members includes this workshop. If you fall under this category, you may register for free (ask Crystal Nyitray for the code).

A light snack and coffee is included for all sessions. Acceptance into a future course is guaranteed with a waived fee if the company’s application is unsuccessful.

Have questions about QB3 NIH/NSF SBIR Workshop Spring 2016 at UCSF? Contact QB3 Details and registration at https://www.eventbrite.com/e/qb3-nihnsf-sbir-workshop-spring-2016-at-ucsf-tickets-19712585875?mc_eid=cb4c38a44a&mc_cid=b99e62a819

UC Berkeley: Four sessions Dates: Starts Wed. Jan. 20, ends Wed. Mar. 16 Location: Stanley Hall, UC Berkeley QB3 NIH SBIR Workshop Spring 2016 at Berkeley

QB3 Wednesday, January 20, 2016 at 1:00 PM - Wednesday, March 16, 2016 at 4:00 PM (PST) Berkeley, CA Register now for the QB3 NIH/NSF SBIR Workshop at UC Berkeley

Four two-and-a-half hour SBIR classes, starting Wednesday, January 20th and concluding Wednesday, March 16th. There are a limited number of seats, so please sign up as soon as possible by registering here on Eventbrite.

This four-session workshop will take you through all the steps necessary to successfully file a well-written SBIR/STTR grant application for the April 5 NIH SBIR deadline. This course will focus on crafting a well-structured research plan, getting persuasive letters of support, crafting an efficient budget, and helping you anticipate reviewers’ comments. We will help you speed through the application instructions, saving you hours of time. The course

culminates in a submission clinic that will ensure your application is correctly filed. One or more team members from the company should be prepared to attend every session. Remember to bring your laptop; these will be working sessions. Topics include

• Understanding the requirements of an SBIR • Preparing to apply for an SBIR (company formation, registration at all required websites, identifying the best PI) • Assembling all the necessary parts of the application (letters of support, sub-contract

quotes and letters, facilities to execute the grant, and research plan) • Composing a competitive research plan • Understanding and assembling a budget and justification • Documentation required to use human samples, vertebrate animals, select agents,

resources • Composing competitive innovation and significance sections as well as specific aims • Searching for program announcements and finding opportunities • Assembling and filing (completing the 424 correctly and filing on time)

Schedule Dates Time Location 1/20 (Weds) 1:30-4:00 pm Stanley Hall 177 2/10 (Weds) 1:30-4:00 pm Stanley Hall 177

3/2 (Weds) 1:30-4:00 pm TBD 3/16 (Weds) 1:30-4:00 pm TBD

9

Instructors: Gabrielle G. Leblanc, PhD, Bioscience Consulting Crystal Nyitray, PhD, Entrepreneurship Program Manager

Standard rate for the entire 14-hour workshop: $750 per company Discounted rate for UC affiliates, QB3 Startup in a Box Members, and QB3 Accelerator Members: $250 for entire course per company The QB3 Startup in a Box membership fee for new members includes this workshop. If you

fall under this category, you may register for free (ask Crystal Nyitray for the code). A light snack and coffee is included for all sessions.

Acceptance into a future course is guaranteed with a waived fee if the company’s application is unsuccessful. DetD

Course Description For entrepreneurs looking for non-dilutive federal funding to get life science startups off the

ground. We walk you through your grant application to ensure you complete everything properly and submit by the April 5 NIH deadline. Entrepreneurs applying through the QB3 workshop are 3x more likely than the nationwide average to get funded! See the individual registration pages for class dates and locations. The UCSF thread includes

a special focus on NSF SBIRs, Phase 2 awards, and resubmission. Find details and registration at https://www.eventbrite.com/e/qb3-nih-sbir-workshop-spring-2016-at-berkeley-tickets-19712795502?mc_cid=b99e62a819&mc_eid=cb4c38a44a ************************************************************************

GGPF,Tuesday Evening, Jan. 19, 2015 Topic: "Multi-functional Liquid Crystalline Epoxy Networks" Speaker: Prof. Michael R. Kessler, School of Mechanical and Materials Engineering, Washington State University, Pullman, Washington Date and Time: Tuesday, Jan. 19, 2015, 6:00 PM social hour; 7:00 PM dinner; 8:00 PM presentation Location: Michael's at Shoreline, 2960 N Shoreline Blvd, Mountain View Cost: Employed/postdocs: $30 early registration, $35 regular registration Unemployed/retired/students: $15 early registration, $20 regular registration Free if you attend just the lectures at 8:00 PM (but please let us know for headcount) After deadline: Registration not guaranteed, so contact us Late fee applies if space available -- $40 regular/employed, $25 unemployed/student/retired Deadlines for registration: End of discounted advance registration Monday, Jan. 11, 11:59 PM End of regular (full-price) registration Monday, Jan. 18, 5:00 PM Because we must pay the restaurant for the ordered meal, we must ask no-shows to pay for their reservation. However, penalty-free cancellations are allowed up until the deadline for reservations (Monday, Jan. 18, 5:00 PM) PLEASE NOTE:

10

We accept cash or checks at the door, but are unable to accept payment by credit card at the event. You may pay at the door. Checks may be made to "GGPF" Please register on the web page Or, if necessary, contact: Nayan Ashar nayandevyani@gmail.com<mailto:nayandevyani@gmail.com> 408-316-1619 You should receive confirmation of your registration; if not, please contact us again. Topic Description Liquid crystalline networks (LCNs) are versatile functional materials because of the unique properties of liquid crystalline molecules, e.g., self-organization, reversible phase transition, and macroscopic orientation under external fields. The coupling between LC molecules and polymer networks allows these remarkable properties to be transferred to the bulk material and has resulted in a number of functional LCNs that are thermally-responsive and can change their shape reversibly due to the reversible LC phase transition upon temperature cycling. The incorporation of photo-responsive chromophores into LCNs allows the material to convert light energy into mechanical work because of the transformation between two geometrically different azobenzene isomers upon light irradiation. Here we demonstrate a simple route to incorporate three functional building blocks, including azobenzene chromophores, liquid crystals, and dynamic covalent bonds, together into a liquid crystalline epoxy network. The three functionalities show good compatibility and the resulting material can exhibit various photomechanical responses, dual-stimuli induced shape memory and self-healing properties, and excellent processability and recyclability. Speaker Bio Dr. Michael R. Kessler is the Berry Family Director and Professor of the School of Mechanical and Materials Engineering at Washington State University. As the chief academic and administrative officer for the school, he is responsible for teaching, research, and outreach in the mechanical and materials engineering programs. His research and teaching interests are in the mechanics, processing, and characterization of polymer matrix composites, nanocomposites, and bio-based polymers. Prior to joining the faculty at Washington State University, he held faculty positions at Iowa State University and the University of Tulsa. He obtained his Ph.D. in Theoretical and Applied Mechanics from the University of Illinois at Urbana-Champaign. His honors include Young Investigator Awards from the Army Research Office and the Air Force Office of Scientific Research, an NSF CAREER award, and the Elsevier Young Composites Researcher Award from the American Society for Composites. He has published over 150 journal papers, holds six patents, edited a book on the characterization of composite materials, presented more than 100 talks at national and international meetings, and serves as a frequent reviewer and referee in his field. **************************************************************************************************

QB3, Wednesday Afternoons, Jan. 20, 2016

Event: QB3 NHI SBIR Workshop (Berkeley Edition) Instructors • Gabrielle G. Leblanc, PhD, Bioscience Consulting

• Crystal Nyitray, PhD, Entrepreneurship Program Manager Date and Time: January 20 through March 16, 2016 Schedule Date Time Location 1/20 (Wed) 1:30-4:00 pm Stanley Hall 177 2/10 (Wed) 1:30-4:00 pm Stanley Hall 177

11

3/2 (Wed) 1:30-4:00 pm TBD 3/16 (Wed) 1:30-4:30 pm TBD

Location: UC Berkeley, Stanley Hall, Room 177, Berkeley, CA 94720 Fees etc. Standard rate for the entire 14-hour workshop: $750 per company Discounted rate for UC affiliates, QB3 Startup in a Box members, and QB3/CLS Accelerator members: $250 for entire course per company The QB3 Startup in a Box membership fee for new members includes this workshop. If you fall under this category, you may register for free (ask Crystal Nyitray for the code). A light snack and coffee is included for all sessions. Acceptance into a future course is guaranteed with a waived fee if the company’s application is unsuccessful. Register at http://www.eventbrite.com/e/qb3-nih-sbir-workshop-spring-2016-at-berkeley-

tickets-19712795502?mc_cid=63b78945b7&mc_eid=cb4c38a44a NHI SBIR Course Description For entrepreneurs looking for non-dilutive federal funding to get life science startups off the

ground. We walk you through your grant application to ensure you complete everything properly and submit by the April 5 deadline. Entrepreneurs applying through the QB3 workshop are 3x more likely than the nationwide average to get funded! Four two-and-a-half hour SBIR classes, starting Wednesday, January 20th and concluding

Wednesday, March 16th. There are a limited number of seats, so please sign up as soon as possible This four-session workshop will take you through all the steps necessary to successfully file a well-written SBIR/STTR grant application for the April 5 NIH SBIR deadline. This course

will focus on crafting a well-structured research plan, getting persuasive letters of support, crafting an efficient budget, and helping you anticipate reviewers’ comments. We will help you speed through the application instructions, saving you hours of time. The course culminates in a submission clinic that will ensure your application is correctly filed. One or more team members from the company should be prepared to attend every session. Remember to bring your laptop; these will be working sessions. Topics Include • Understanding the requirements of an SBIR • Preparing to apply for an SBIR (company formation, registration at all required

websites, identifying the best PI) • Assembling all the necessary parts of the application (letters of support, sub-contract quotes and letters, facilities to execute the grant, and research plan) • Composing a competitive research plan

• Understanding and assembling a budget and justification • Documentation required to use human samples, vertebrate animals, select agents, resources • Composing competitive innovation and significance sections as well as specific aims

• Searching for program announcements and finding opportunities • Assembling and filing (completing the 424 correctly and filing on time)

*********************************************************************

PBSS Workshop, Friday, Jan. 22, 2016 Topic: “Drug Delivery and Controlled Release: Fundamentals, Technologies and Case

Studies” Date: Friday, January 22, 2016; 8:45-17:00

12

Location: SF Bay Area: Foster City Crowne Plaza Registration fee (US$): For unemployed & students: $30; For vendor-show rep: $35; Regular: $195; For major-sponsor rep (incl lunch): $0; Registration: http://www.PBSS.org

Registration deadline:1/20/2016 (it will close sooner if the seating cap is reached) ******************************************************************** CABS, Saturday, Jan. 23, 2015 CABS Seminar: Diagnosis and Treatment of Acute Heart Attack

Speaker: Dr. Ling, Board Certified Primary Care Physician Date and Time: 2016-01-23 Time: 1:00-3:00PM Location: Foster City Recreation Center, Mist Room 650 Shell Blvd, Foster City, CA 94404 Registration is free.

Seminar Description Heart attack remains a leading cause of death in US and worldwide. Heart attack can result in critical reduction of blood and oxygen supply to heart for an extended period, which can

cause irreversible heart muscle damage or death. It is important to control or eliminate the risk factors of heart attack. Also, it is critical to recognize the symptoms of a possible heart attack and take the appropriate action. From this seminar, you will gain a better understanding of this disease, which is your first

step to fully embracing self-care. Dr. Lin will teach you some tips to help you develop an effective self-care plan. Speaker Bio

Dr. Ling, Board Certified US Primary Care Physician. Before start of her own clinic in Burlingame, she

worked as a staff physician at Asian Health Services in Oakland, CA. was raised in a family of doctors, having started practice in 1992. Prior to coming to US, she worked as an attending physician for over 6 years at Peking Union Medical College Hospital in Beijing, the best hospital in China and accumulated much experience from the world-known experts in

different fields. Dr. Ling is a board-certified physician in US, Primary Care Physician. She finished USMLE exams with scores of 99% and finished her residency in New York. Before start of her own clinic in Burlingame, she worked as a staff physician at Asian Health Services in Oakland, CA. In addition to her medical training, Dr. Ling received her Ph.D in

Pharmaceutical Sciences with GPA of 4.0 and received Pfizer Recognition Award and Johnson & Johnson Standards of Leadership Award, for her work on Clinical Trials in the fields of diabetes, oncology, etc. Her expertise in drug mechanisms and drug-drug interactions means that she can provide patients with the best personalized care, and the

best medicine combination with minimal side effects. Even with years of experience, she always takes her time to give the best care for each individual patient. Her clinic address: 1828 El Camino Real #405, Burlingame, CA 94010. Her website: DrJennyLing.com

Registration Requirement: Free ****************************************************************** PMWC, Monday – Wednesday, Jan. 24-27, 2016 Event: Personalized Medicine World Conference

Date and Time: Monday, January 25, 2016 at 7:00 AM -Wednesday, January 27, 2016 at 5:00 PM (PST) Location: Computer History Museum 1401 N Shoreline Blvd Mountain View, CA 94043

See program details at http://2016sv.pmwcintl.com/all/ Price: $1,000 prior to Oct. 15 and then $2,500 through Jan. 24, 2015

13

Register at https://www.eventbrite.com/e/pmwc-2016-sv-attendees-tickets-14926919819 Event Description

The Personalized Medicine World Conference (PMWC) is the only fully integrated conference to examine the advances and challenges of Personalized Medicine through a practical lens. PMWC brings together the thought-leaders of business, government, healthcare-delivery, research and technology into one information-rich, two-day conference.

Tickets are not refundable! These individuals all have played, and continue to play, tremendously critical roles in shaping the human healthcare system, changing it from a general population approach to a personalized and patient-centered care model. For this reason, their outstanding

contributions to medicine will be recognized by awarding them the Pioneer and Luminary Awards at the upcoming Personalized Medicine World Conference 2016 Silicon Valley on January 24-27. The Luminary Awards will be presented to Dr. Roger Perlmutter for transforming two R&D

organizations and for the development of groundbreaking new therapies, and to Dr. Esserman for her visionary approach towards breast cancer medicine. The Pioneer Awards will go to Dr. Ralph Snyderman, referred to as the “father of personalized medicine”, and to Dr. Irv Weissman, similarly referred to as the “father of

hematopoiesis”.

Join 1,100 peers in Silicon Valley on January 24 - 27, 2016 With more than 65 sessions, 130 speakers and three parallel tracks

Building on the groundwork for transformative patient-centered health care at PMWC 2016 Silicon Valley

The adoption of personalized medicine is being driven by a multitude of advancements across different disciplines that thrive on technological innovations. Next-generation sequencing (NGS), computational power and mechanism-based biology are all contributing to better disease diagnosis, prognosis and treatment. As such, more and more individuals undergo NGS-based diagnostic testing, primarily in the area of oncology. With these advancements and the President’s Precision Medicine Initiative it is expected that in the near future we not only see larger populations getting tested, but also having their DNA fully sequenced. The value of NGS in this context is indisputable and as such we can observe a strong interplay with the clinic — clinical adoption drives innovation even as NGS drives new applications. As NGS adds to the identification and application of new biomarkers, contributes to the understanding and characterization of the underlying biology of human diseases, and aids in the identification and characterization of new drug targets, a number of non-trivial challenges arise, such as increasing complexity in clinical trial design and patient selection, and increased pressure to provide justification of clear clinical value to both payers and patients.

The tenth Personalized Medicine World Conference (PMWC 2016), which will take place from January 24 - 27 in Silicon Valley, will focus on these developments in a collegial setting that fosters scientific exchange, networking and

partnering. The broad array of topics covered span biological, engineering and

14

computational advancements as well as research and commercial applications, and the conference will touch upon issues such as data privacy and security, regulatory updates and commercial opportunities. Lastly, a panel on "NGS & Clinical Interplay” will provide multi-faceted perspectives from Helix’s new CEO, Peter Yu (ASCO), Cliff

Reid (Complete Genomics), Rick Klausner (Illumina), Allison Ballmer (Roche), Jonas Korlach (PacBio) and others. For more, visit us at: http://2016sv.pmwcintl.com

Follow us on Twitter to get more updates: @PMWCintl

LUMINARY AWARD RECIPIENTS

Laura Esserman, MD, MBA, is a recognized breast surgeon and breast oncology specialist at the University of California, San Francisco leading a groundbreaking national public-private collaboration combining personalized medicine with a novel trial design, which has now become the new model for translational research. Dr. Esserman is currently focusing on a 100,000 women breast cancer screening study to determine whether a personalized approach to screening and treatment is safer and more effective. Read Full Bio

Roger M. Perlmutter, MD, Ph.D, (President, Merck Research Laboratories and previously Amgen) transformed two major R&D organizations and enabled the expeditious development and subsequent approval of small molecule and biologic

medicines including the monoclonal antibody Denosumab (for the for the treatment of osteoporosis) and the anti-PD1 therapy, Keytruda, to treat metastatic melanoma.

PIONEER AWARD RECIPIENTS

Ralph Snyderman, MD (Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine), who has created a transformative environment to improve our nation’s health over the last 40 years. During this time, he led the transition of the School of Medicine at Duke University into a globally recognized leader of academic medicine and played a

leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and

participatory care that is focused on the patient.

Irv Weissman, MD (Director of the Institute of Stem Cell Biology & Regenerative Medicine at Stanford School of Medicine), contributed to the understanding of

hematopoiesis and moved the field of stem cell research forward to make successful treatments a reality. Not only was he instrumental in isolating the first blood-forming stem cells in mice and humans early on, he is also recognized for isolating human Leukemia cancer stem cells. His work and discoveries on stem cell

aging contributed to the understanding of cancer stem cells and the immune system and are pioneering achievements with far-reaching clinical applications.

15

****************************************************************** JLABS, Tuesday Morning, Jan. 26, 2016

Event: Meet with…Canaan Partners Speaker: Wende Hutton | General Partner, Canaan Partners Date and Time: Tuesday, Jan. 26, 2016, 10:30 am – 1:00 pm Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees: Presentation & Lunch $25 | General Public $35 | General Public Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until January 25th, 2016 (or sold out).

One-on-One Meeting FREE | Application FREE | Accepted Companies Companies must have applied for a one-on-one meeting ahead of time. The one-on-

one application period ends on December 1st, 2015. Your application will be reviewed and you will be notified of acceptance by January 5th, 2016 . Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Register at http://www.eventbrite.com/e/meet-with-canaan-partners-tickets-18496128418?aff=blast#s1 Event Description Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary

ideas. With $4.2 billion under management and over 180 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, and Civitas Therapeutics. Canaan recently announced Fund X, a $675 million fund

focused on early stage IT and healthcare startups. The fund's healthcare focus inclu Wende Hutton, General Partner, will be in attendance on January 26th to provide an overview presentation of Canaan's areas of interest and best practices when applying for

funding. Following the presentation, don't miss this opportunity to introduce yourself to Wende during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Wende will provide a forum to discuss your company.

Speaker Bio Wende Hutton | General Partner, Canaan Partners Healthcare investor Wende Hutton brings 20 years of experience to identifying,

investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Butterfly Health, Chrono Therapeutics, Dermira, Glooko, ReVision Optics, Theraclone Sciences and Transcend Medical. Prior investments include BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), and Labrys Biologics

(acquired by Teva Pharmaceutical). Wende was recognized among Fierce Biotech’s 2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women

16

in Bay Area Business 2015 by The San Francisco Business Times. Wende joined Canaan in 2004, and her life sciences track record includes seven IPOs and five acquisitions. She began her venture career at Mayfield Fund in 1993, where she worked closely with the founding teams of Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier

in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing. Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of FACE AIDS.

************************************************************ JLABS, Thursday Morning, Jan. 28, 2015

Event: Science 1st - Designing Nucleic Acid Medicines Speakers: Michael McManus | Associate Professor, UCSF School of Medicine read bio»

David Schaffer | Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, UC Berkeley / Director, Berkeley Stem Cell Center read bio» Laura Sepp-Lorenzino | VP, Entrepreneur-in-Residence, Alnylam Pharmaceuticals read

bio» [moderator] Beth Hill | Senior Director, Platform Innovation, Johnson & Johnson Innovationread bio» Date and Time: Thursday, Jan. 28, 2015, 8:30 – 11:45 am Agenda: 8:30am | Registration Opens, Networking and Breakfast 9:25am | Introduction 9:30am | Presentation and Q&A 11:15am | Panel Discussion and Q&A 11:45am | Close Location: UCSF - Byers Auditorium, Genentech Hall,600 16th St , San Francisco, CA 94158 Fees: $25 General Public - pre-registration will remain open until 5:00pm on Jan 27th $15 Student/Academic - pre-registration will remain open until 5:00pm on Jan 27th $35 At the door - at the door registration will open at 8:30pm on Jan 28th Details and registration at http://www.eventbrite.com/e/science-1st-designing-

nucleic-acid-medicines-tickets-18375547758?aff=weekly About the Science First series:

The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings together top experts to explore pressing topics in their scientific fiel d. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.

Speakers' Biographies: Michael McManus, Ph.D. | Associate Professor, ‎UCSF School of Medicine

Dr. McManus obtained his Ph.D. from the University of Alabama in Birmingham, where he studied RNA editing in the laboratory of Stephen L. Hajduk. In 2000, he did

17

his postdoctoral training as a Cancer Research Institute fellow, in the laboratory of Nobel Laureate Phillip A. Sharp at the Massachusetts Institute of Technology (MIT), studying the role of RNA-interference pathways in mammals. He is appointed as an Associate Professor at the University of California San Francisco, in the Department

of Microbiology and Immunology. He is the founder and Director of the W.M. Keck Center for Noncoding RNAs and also oversees the Sandler Lentiviral RNAi Core at UCSF. He has a long-standing interest in post-transcriptional gene regulation and the role of small RNAs in gene expression. ^ Back to Speakers' list ^

David Schaffer, Ph.D. | Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, University of California at Berkeley /

Director, Berkeley Stem Cell Center David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He graduated from Stanford

University with a B.S. degree in Chemical Engineering, and from Massachusetts Institute of Technology with a Ph.D. in Chemical Engineering. He did a postdoctoral fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in La Jolla, CA. At UC Berkeley, Dr. Schaffer applies engineering principles to enhance

stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.

Connect with David:

^ Back to Speakers' list ^ Laura Sepp-Lorenzino, Ph.D. | VP, Entrepreneur-in-Residence, Alnylam

Pharmaceuticals Laura Sepp-Lorenzino, Ph.D. is Entrepreneur-in-Residence at Alnylam Pharmaceuticals, a leading Cambridge MA biopharmaceutical company developing novel therapeutics based on RNA interference. Dr. Sepp-Lorenzino joined Alnylam in

2014, and is leading the Hepatic Infectious Disease Strategic Therapeutic Area. Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and

development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point, and having been an Assistant Lab Member at Memorial Sloan-Kettering

Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.

Connect with Laura: ^ Back to Speakers' list ^ [moderator] Beth Hill, Ph.D. | Senior Director, Platform Innovation, Johnson & Johnson Innovation Beth Hill is Senior Director of Platform Innovation at Johnson & Johnson Innovation,

18

California. She is an experienced pharmaceutical innovator with many years of strategic and operational leadership in creating and applying technologies that overcome technical and business barriers. Formerly with Janssen R&D, Beth led global cross-disciplinary functions working from late discovery through development

and commercialization with a focus on drug delivery and drug+device combination products. Beth has also led R&D teams to develop therapeutics for cancer and autoimmune disease. At Systemix /Novartis she held functional and project leadership roles in stem, somatic cell and gene therapies. She began her industrial career developing antibody-based diagnostics at Syva Co. Beth earned her BA in

Medical Technology at Augustana College, her PhD in Microbiology at Columbia University, and completed her post-doctoral studies in the Stanford Department of Structural Biology.

Connect with Beth: *************************************************************************************************

JLABS, Tuesday Morning, Feb. 2, 2016

Topic:” Between Two Benches: From corporate to entrepreneur and back… Speakers: Uri Lopatin | Chief Medical Officer & Vice President of R&D, Assembly Biosciences [interviewer] Jeff Calcagno | New Ventures Johnson & Johnson Innovation Date and Time: Tuesday, Feb. 2, 2015, 11:30 am 11:30am | Registration Opens, Lunch and Networking 12:00pm | Presentation, Interview and Q&A 1:00pm | Program Close Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California Fees: $25 | General Public $15 | Academic/Student Rate $35 | At the door Details and registration at http://www.eventbrite.com/e/between-two-benches-from-corporate-to-entrepreneur-and-back-tickets-19250834765?aff=weekly Event Description Healthcare entrepreneurs start companies to create solutions that ultimately benefit patients; but this is a long journey, with few road signs along the way. Join us on February 2 to hear insights and lessons learned from a successful founder and CMO of one of the first JLABS @ 953 "graduates", Assembly Biosciences.

Uri Lopatin, Founder and Chief Medical Officer at Assembly Biosciences (ASMB) will be interviewed by Jeff Calcagno of Johnson & Johnson Innovation. The conversation will focus on the making of a healthcare entrepreneur, how he navigated his way from academia to big biotech to start up, and how he and his teammates-with help from Johnson & Johnson Innovation-led Assembly Biosciences from seed stage to public company in less than two years. The pair will be look at the highlights of Uri's journey, including early mistakes and successes, surprises, lessons learned from working with investors and with Johnson & Johnson Innovation, and more. Don't miss the opportunity to learn from this lively and candid discussion between

19

two individuals who are making a difference in the biotech space. The Inspiring Leader Series provides an intimate forum for biotech veterans and experts to share their career successes and challenges. Each accomplished speaker

shares lessons learned over the course of his or her professional adventure. The audience is comprised largely of entrepreneurs getting ready to embark on his or her own company-building journey. The series is an interactive and inspiring experience. Speaker Bios

Uri Lopatin, M.D. | Chief Medical Officer & Vice President of R&D, Assembly Biosciences Dr. Lopatin is a co-founder and the Chief Medical officer and VP R&D for Assembly Pharmaceuticals, Inc. Prior to Assembly, he was a Senior Director for Clinical and

Translational Research-Liver Disease at Gilead Sciences, a Translational Medical Leader at Roche, and an Associate Director at Schering Plough. He has designed and coordinated pre-clinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published

extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at

NYU. He received his MD in 2000 from University of Medicine and Dentistry-New Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.

Connect with Uri: Jeff Calcagno, M.D. | New Ventures, Johnson & Johnson Innovation Jeff is a senior operating and business development executive focused on healthcare innovation. He is based in Johnson & Johnson's California Innovation Center, which

he helped to establish. He is a member of the New Ventures team, which is responsible for identifying promising new technologies for Johnson & Johnson (J&J), the world's largest healthcare company, and for structuring optimal business relationships. Jeff's career has spanned healthcare and business for over two decades

and has included roles as a management consulting at McKinsey & Company and as a research analyst at JP Morgan H&Q. A former entrepreneur who has raised over $50MM in venture money, he ran corporate development for WIDCOMM, a technology company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals,

a venture-backed drug development company. From 2006 to 2010 he was a Principal & Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under management. Jeff graduated Phi Beta Kappa in Biology from Harvard College and earned an M.D. from Harvard Medical School. He completed his psychiatry residency

at UCLA's Neuropsychiatric Institute and was chosen as program chief resident. Afterwards, he was awarded and completed a clinical neuropharmacology fellowship focusing on the care of treatment-refractory patients. A former Rotary International Ambassadorial Scholar, Jeff is conversational in six languages.

*********************************************************************************************** Seminars at Stanford, Mid Day, Feb. 9, 2016 Topic: “Novel Technologies to Investigate the Stem Cell Niche”

Date and Time: Feb. 9, 2016, 12:00 pm Location: Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

20

Event Details: Small Lunch Served At 12:00��; Lectures Begin At12:15�� Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360 February 9, 2016

Pre-Seminar Speaker: Michael Lin, Departments of Pediatrics and Bioengineering February 11, 2016

Seminar Speaker: David Schaffer, UC Berkeley Novel Technologies to Investigate the Stem Cell Niche **********************************************************************

ACRP, Thursday Afternoon, Feb. 11, 2015

Event: Mark Your Calendars for the ACRP Virtual Career Fair

Date and Time: Thursday, February 11, 2016 from 9:00 am – 1:00 pm PT (12:00 pm – 4:00 pm EST ) Details and registration at https://app.brazenconnect.com/events/acrp-career-fair#!eventLanding;eventCode=acrp-career-fair

The ACRP Virtual Career Fair is an excellent resource for clinical research professionals, like yourself, to connect with the nation's top employers. Create or Update your Job Seeker Profile NOW and don't forget to flag your resume as a participant in the Virtual Career Fair!

How the event works:

Discover potential career opportunities, have your resume reviewed, conduct interviews via online chat and follow-up with recruiters and employers that

interest you Scout open positions more confidentially than at an onsite career fair Connect with top clinical research employers regarding their current and future

hiring needs Click here to ensure your professional profile is up-to-date

*********************************************************************** JLABS, Thursday MidDay, Feb. 11, 2016

Topic: “Lessons in Herding Cats – Business Development Basics for Life Science Companies” Speaker: Lesley Stolz, Ph.D. | Sr. Director, Transactions, Johnson & Johnson Innovation,

California Date and Time: Thursday, February 11, 2016 from 10:45 AM to 1:00 PM (PST) Agenda: 10:45 AM | Registration Opens

11:00 AM | Presentation 12:00 PM | Q&A 12:15 PM | Lunch and Networking 1:00 PM | Program Close Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd., 3rd Floor, South

San Francisco, CA Fees: $35 | General Public $20 | Student/Academic

$45 | Onsite

21

Register at http://www.eventbrite.com/e/lessons-in-herding-cats-business-development-basics-for-life-science-companies-tickets-19858437120 Topic Description

The business development professional's purpose is to optimize optionality and long term value at each stage of a company's life. As a company grows and gains traction, it's easy to get enticed and overwhelmed by the numerous opportunities that arise. How do you determine the direction that will add the most value to your company? How do you avoid the constant pursuit of "shiny objects?" How do you know when it's the right time for a

strategic partnership? In this workshop, you'll learn fundamental business development skills to help you successfully evaluate and manage strategic alliances and other potential growth

opportunities. Topics will include:

Strategic alliance process management

Concepts in valuation Importance of IP and IP diligence Communication and negotiation skills Basic components of a contract

This workshop is geared towards business development professionals and management teams of life science startups.

Speaker Bio Lesley has been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused. Her most recent executive positions have been with BioTime, a publicly traded stem cell technology and

therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech companies in the U.S. and Europe. Lesley received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and

Molecular Pharmacology.

*****************************************************************

JLABS, Thursday, Feb. 26, 2016

Topic: “Meet with….Sofinnova Ventures” Speaker: Mike PowellSofinnova Ventures Participating Representative Date and Time: Thursday, Feb. 26, 2016; 10:30 am to 1:00 pm Agenda: 10:30am | Registration Opens and Networking 11:00am | Presentation and Q&A 11:45am | Networking Lunch 1:00-5:00pm | One-on-one Meetings*

22

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on January 25th, 2016. Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees: Presentation & Lunch $25 | General Public $35 | General Public Onsite Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of

one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until February 24th, 2016 (or sold out). One-on-One Meeting

FREE | Application FREE | Accepted Companies Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on January 25th, 2016. Your application will be reviewed

and you will be notified of acceptance by February 11th, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. Register at http://www.eventbrite.com/e/meet-with-sofinnova-ventures-tickets-18715680103?aff=blast

Topic Description Are you Sofinnova material? Sofinnova Ventures, a leader in funding for life sciences companies, is visiting Johnson & Johnson Innovation, JLABS. With $2 billion under

management and a recent $500 million fund, Sofinnova is looking to invest in life science innovators. Focus areas include clinical drug development and drug discovery. Since 1974, Sofinnova has partnered with entrepreneurs to secure initial funding,

build successful management teams, form impactful corporate alliances, win key customers, and navigate acquisitions and IPOs. Sofinnova applies capital and expertise to guide start-up companies to successful exits. Recent exits include Labrys Biologics, Tesaro, and Spark.

Representatives from Sofinnova will be in attendance to give an overview presentation about the company's key areas of interest and best practices when seeking startup funds. Following the presentation, don't miss this opportunity to

introduce yourself to Mike Powell , General Partner, during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Sofinnova will provide a forum to discuss your company.

Speaker Bio Mike Powell, Ph.D. | General Partner, Sofinnova Ventures Mike joined Sofinnova in 1997, and SVP IX ($510M) is his sixth Sofinnova fund. He has 32 years of experience, including 15 years of R&D before venture. Mike has been

involved in more than 50 clinical programs, and is the author of 90 publications and books, including a 1,000-page treatise on vaccine design. He was the initial venture investor of: Actelion (ATLN), Intermune (ITMN), Orexigen (OREX), Seattle Genetics (SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to

Teva). Mike was the first person in the biotech industry to be honored by the American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also

23

served on the journal editorial boards of Journal of Pharmaceutical Sciences and the Journal of Controlled Release. He has been the Board President of the AIDS Vaccine Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI, and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in

the Department of Pharmaceutical Chemistry at the University of Kansas, one of the top US pharmacy schools. Before joining Sofinnova, he was group leader of drug delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen, an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director of Product Development. Before this he was Senior Scientist and Project Team Leader

at Syntex Research. Mike received his PhD in Chemistry from the University of Toronto and carried out postdoctoral studies in bio-organic chemistry at the University of California as a National Science and Engineering Research Council Scholar. Mike and his wife Tana live in San Francisco, and they enjoy flying, skiing,

diving and flyfishing. Connect with Mike: Connect on LinkedIn *****************************************************************

PBSS, Monday, Feb. 29, 2016 Workshop: Advanced LC/MS Practices Speakers: Jack Henion, Ph.D. Emeritus Professor of Analytical Toxicology, Cornell University

Date: Monday, February 29, 2016, 8:45-17:00 Location: SF Bay Area: Foster City Crowne Plaza Registration fee (US$): Regular: $195; For unemployed & students: $30; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35; For others, details available upon online

login. Registration: http://www.PBSS.org Further Information: Registration deadline: 2/26/2016 (it will close sooner if the seating cap is reached)

About the Topic Course Objective: Learn effective LC/MS techniques for analyzing complex samples and characterizing organic compounds

Who Should Attend: Experienced LC/MS researchers and practitioners, or others involved in identifying or measuring organic compounds in real-world samples including drugs and metabolites within

or for the pharmaceutical industry, and who work with HPLC and MS techniques. Prior HPLC and/or LC/MS experience and understanding is assumed. Key Topics You'll Learn About:

Principles and preferred practices for APCI LC/MS Fundamentals and practices for optimal electrospray ionization Principles of multiple charging in electrospray mass spectra of biomolecules Strategies for characterizing small molecules contained in biological samples via

electrospray LC/MS and LC/MS/MS. Sample preparation optimized for LC/MS and LC/MS/MS analyses Initial strategies for interpreting collision-induced dissociation (CID) mass spectra of

small pharmaceutical molecules.

About the Speakers

24

Jack Henion is Professor Emeritus of Toxicology at Cornell University in the Analytical Toxicology.. He is also a co-founder, Chairman, and CSO of Advion BioSciences, Inc., located in Ithaca, New York. Prof. Henion’s work in LC/MS relates to the analysis of real-world samples common to pharmaceutical, environmental, and biochemical problems. The

instructor has published extensively in the areas of conventional capillary GC/MS as well as LC/MS, SFC/MS, IC/MS, and CE/MS using atmospheric pressure ionization (API) technologies with quadrupole, ion trap, FTMS, and time-of-flight mass spectrometers. ********************************************************************* Bio2Device Group, Tuesday Evening, August 9, 2016

Topic: TBA Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm

Date and Time: Tuesday, Oct. 13, 2015, 6:00pm Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA Cost: $6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins (as space permits) Register at www.Bio2DeviceGroup.org

Speaker Bio

Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in San Francisco and leads the company’s life sciences practice on the west coast of the

US. She joined the team in San Francisco in August 2012 after spending 5 years in Simon-Kucher’s Boston office. In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-to-customer, market entry strategies, pricing and market access strategies, innovative pricing strategies, product lifecycle strategies, licensing and valuation, market

forecasting and value communication, including global value story development and implementation. She is a trusted advisor of leading pharmaceutical and biotech companies across a wide range of therapeutic areas in all major healthcare markets across the globe.

Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from Yale University and a B.A. in Physics with honors from Wellesley College where she was a Goldwater Scholar and a Schiff Fellow. She is the author and coauthor of several scientific publications and has research

experience in theoretical and experimental physics, biophysics, cell biology, cancer biology, genomics, proteomics, bioinformatics and biochemistry.